Document is current
Any future updates will be listed below
-
Authors
Liddell, Jeffrey R. http://orcid.org/0000-0002-0798-5338
Hilton, James B. W. http://orcid.org/0000-0002-2657-3566
Kysenius, Kai http://orcid.org/0000-0003-1038-2850
Billings, Jessica L.
Nikseresht, Sara
McInnes, Lachlan E.
Hare, Dominic J.
Paul, Bence
Mercer, Stephen W.
Belaidi, Abdel A.
Ayton, Scott
Roberts, Blaine R.
Beckman, Joseph S.
McLean, Catriona A.
White, Anthony R.
Donnelly, Paul S.
Bush, Ashley I.
Crouch, Peter J. http://orcid.org/0000-0002-7777-4747
-
Funding
Funding for this research was provided by:
Motor Neurone Disease Australia
FightMND
National Health and Medical Research Council
Perpetual IMPACT Philanthropy
The University of Melbourne
- License Information
-
More Information
Article History
Received: 20 October 2023
Accepted: 28 November 2023
First Online: 5 February 2024
Change Date: 17 February 2024
Change Type: Update
Change Details: The original article was corrected to resolve ESM labelling errors.
Declarations
:
: The use of mice for generating primary cell cultures and assessing the effect of Cu<sup>II</sup>(atsm) was approved by a University of Melbourne Animal Experimentation Committee (Projects 1613931, 1814576, and 1915081) and complied with National Health and Medical Research Council guidelines. Procedures involving post-mortem human tissue were approved by a University of Melbourne Human Ethics Committee (Projects ID 1238124 and 1750665).
: Not applicable.
: Collaborative Medicinal Development LLC has licensed intellectual property related to this subject from the University of Melbourne where the inventors include ARW and PSD. AIB is a shareholder in Alterity Ltd, Cogstate Ltd, Brighton Biotech LLC, Grunbiotics Pty Ltd, Eucalyptus Pty Ltd, and Mesoblast Ltd. He is a paid consultant for Collaborative Medicinal Development LLC and has a profit share interest in Collaborative Medicinal Development Pty Ltd. PJC and JSB are unpaid consultants for Collaborative Medicinal Development LLC.
